Liege

• A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting
  2024-517147-31-00 9 2025-05-23 Tumours, Gynecological
• A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping t … Recruiting
  2024-517584-23-00 9 2025-05-16 Duchenne Muscular Dystrophy
• Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia Trial Recruiting
  2024-511828-14-00 4 2025-05-13 Type II diabetes melittus (10067585)
• Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting
  2024-513959-33-00 4 2025-05-13 Asthma
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• Development of an optimized dosing regimen of ceftazidime-avibactam in critically ill patients treated with continuous renal replacement the … Recruiting
  2023-505536-35-00 6 2025-05-04 Ceftazidime-avibactam therapy in critically ill patients undergoing co
• Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting
  2024-514465-18-00 9 2025-04-23 Advanced or Metastatic Non-Squamous NSCLC
• Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administere … Recruiting
  2024-512722-28-00 3 2025-04-22 Eosinophilic esophagitis
• A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti … Recruiting
  2024-513053-69-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• Treatment of ELectroencephalographic STatus epilepticus After cardiopulmonary Resuscitation-2 (TELSTAR-2): a multicenter randomised clinical … Recruiting
  2024-516068-27-01 5 2025-04-10 cardiopulmonary resuscitation
• A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Recruiting
  2023-504904-26-00 5 2025-04-07 Progressive Pulmonary Fibrosis
• Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste … Recruiting
  2023-508507-20-00 5 2025-04-03 Locally advanced or metastatic conventional chondrosarcoma with an IDH
• Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chem … Recruiting
  2023-505773-32-00 10 2025-03-25 Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• PRESERVE-003: ONC-392 (Study Drug) Versus Docetaxel (Standard of Care) in Metastatic Non-small Cell Lung Cancer That Progressed on PD-1/PD-L … Recruiting
  2023-505311-20-01 5 2025-03-21 Metastatic Non-Small Cell Lung Cancer
• Hypertonic lactate after cardiac arrest Recruiting
  2023-506031-15-01 4 2025-02-18 post-anoxic brain injury
• A phase II, multicenter, open-label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subj … Recruiting
  2023-506706-40-00 10 2025-02-11 Mantle-Cell Lymphoma
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
• A placebo-controlled, single-blind, phase I study in healthy volunteers and patients with Rheumatoid Arthritis with ABO21009 Recruiting
  2024-517547-31-00 1 2025-01-31 Rheumatoid Arthritis
• A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad … Recruiting
  2023-505077-32-00 5 2025-01-28 Locally-advanced or metastatic non-squamous non-small cell lung cancer
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col

Showing 193–216 of 639 trials